Granted Patent
B2
US 12,403,119 · App. 15/452,669 · Granted Sep 2, 2025
Treating lymphomas
A61K31/282A61K9/0019A61K31/337A61K38/38A61K39/3955A61K47/643A61K47/6849A61K47/6929C07K16/2887C07K16/30A61K2039/505A61K2039/54A61K2039/545C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This document provides methods and materials related to treating lymphomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD20 polypeptide antibody complexes) to treat lymphomas are provided.
Claims (21)
1. A method for treating a human having lymphoma, said method comprising administering to said human a composition comprising pre-formed nanoparticle/antibody complexes comprising albumin-paclitaxel nanoparticles and an anti-CD20 monoclonal antibody, wherein albumin is complexed to the anti-CD20 monoclonal antibody in the pre-formed nanoparticle/antibody complexes, wherein the nanoparticle/antibody complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the anti-CD20 monoclonal antibody under conditions to form the nanoparticle/antibody complexes, wherein the conditions comprise incubating at least 5 mg/ml aqueous albumin-paclitaxel nanoparticles with the anti-CD20 monoclonal antibody at a weight ratio of 5:1, 5:2, 5:3, 5:4 or 1:1 albumin-paclitaxel nanoparticle to antibody and for between about 5 minutes and about 400 minutes and diluting the pre-formed nanoparticle/antibody complexes prior to administration, such that the nanoparticle/antibody complexes have CD20 binding specificity and an average diameter of said complexes is between 0.15 μm and 0.9 μm; said nanoparticle/antibody complexes suitable for administration under conditions wherein a length of progression-free survival is increased, wherein a B-cell or T-cell expresses CD20.
2. The method of claim 1 , wherein said lymphoma is a Hodgkin lymphoma.
3. The method of claim 1 , wherein the anti-CD20 monoclonal antibody is Rituximab.
4. The method of claim 1 , wherein said composition comprises an alkylating agent complexed with said nanoparticles.
5. The method of claim 4 , wherein said alkylating agent is a platinum compound.
6. The method of claim 5 , wherein said platinum compound is carboplatin.
7. The method of claim 1 , wherein said anti-CD20 monoclonal antibody is a humanized antibody or a chimeric antibody.
8. The method of claim 1 , wherein said composition is administered by injection.
9. The method of claim 1 , wherein said progression-free survival is increased by 15 percent.
10. The method of claim 1 , wherein said composition is suitable for administration under conditions wherein a time to progression is increased.
11. A method for treating a human having lymphoma, wherein said method comprises administering, to said human, a composition comprising pre-formed albumin-containing nanoparticle/antibody complexes, wherein the complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the complexes, wherein the conditions comprise incubating at least 5 mg/ml aqueous albumin-paclitaxel nanoparticles with the anti-CD20 monoclonal antibody at a weight ratio of 5:1, 5:2, 5:3, 5:4 or 1:1 albumin-paclitaxel nanoparticle to antibody and for between about 5 minutes and about 400 minutes and diluting the pre-formed nanoparticle/antibody complexes prior to administration, wherein albumin is complexed to the antibody in the pre-formed albumin-containing nanoparticle/antibody complexes,
wherein an average diameter of said complexes is between 0.15 μm and 0.9 μm, and wherein said antibody is an anti-CD20 monoclonal antibody and the complexes have CD20 binding specificity, wherein a B-cell or T-cell expresses CD20.
12. The method of claim 11 , wherein said lymphoma is a mature B-cell neoplasm or a mature T cell neoplasm.
13. The method of claim 11 , wherein said composition further comprises an anti-inflammatory agent.
14. The method of claim 11 , wherein said administration of said composition is under conditions wherein a median time to progression for a population of humans with said lymphoma is at least 150 days.
15. The method of claim 11 , wherein the average diameter of said complexes is from 0.15 μm to 0.3 μm.
16. The method of claim 11 , wherein the average diameter of said complexes is from 0.3 μm to 0.5 μm.
17. A method for treating a human having lymphoma, wherein said method comprises administering, to said human, a composition comprising pre-formed albumin-containing nanoparticle/antibody complexes, wherein the complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with an antibody under conditions to form the complexes, wherein the conditions comprise incubating at least 5 mg/ml aqueous albumin-paclitaxel nanoparticles with the anti-CD20 monoclonal antibody at a weight ratio of 5:1, 5:2, 5:3, 5:4 or 1:1 albumin-paclitaxel nanoparticle to antibody and for between about 5 minutes and about 400 minutes and diluting the pre-formed nanoparticle/antibody complexes prior to administration, wherein albumin is complexed to the antibody in the pre-formed albumin-containing nanoparticle/antibody complexes,
wherein an average diameter of at least 5 percent of said complexes of said composition is between 0.15 μm and 0.9 μm, and wherein said antibodies are anti-CD20 monoclonal antibodies and the complexes have CD20 binding specificity, wherein a B-cell or T-cell expresses CD20.
18. The method of claim 17 , wherein the average diameter of at least 75 percent of said complexes of said composition is between 0.15 μm and 0.9 μm.
19. The method of claim 1 , wherein the complexes have been pre-formed in vitro by mixing 5 mg/ml or 10 mg/ml aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the complexes.
Continuity (3)
Continuation
15030567
Provisional Application
62012190
· Jun 13, 2014
References Cited (400)
US 4350687A
· Lipton et al.
· 1982
[cited by applicant]
US 5026772A
· Kobayashi et al.
· 1991
[cited by applicant]
US 5116944A
· Sivam et al.
· 1992
[cited by applicant]
US 5216130A
· Line et al.
· 1993
[cited by applicant]
US 5252713A
· Morgan, Jr. et al.
· 1993
[cited by applicant]
US 5260308A
· Poduslo et al.
· 1993
[cited by applicant]
US 5728541A
· Kornblith
· 1998
[cited by applicant]
US 5736137A
· Anderson et al.
· 1998
[cited by applicant]
US 6054297A
· Carter et al.
· 2000
[cited by applicant]
US 6147060A
· Zasloff et al.
· 2000
[cited by applicant]
US 6416967B2
· Kornblith
· 2002
[cited by applicant]
US 6537579B1
· Desai et al.
· 2003
[cited by applicant]
US 6933129B1
· Kornblith
· 2005
[cited by applicant]
US 7041301B1
· Markovic
· 2006
[cited by applicant]
US 7112409B2
· Blumenthal et al.
· 2006
[cited by applicant]
US 7678552B2
· Kornblith
· 2010
[cited by applicant]
US 7731950B2
· Noessner et al.
· 2010
[cited by applicant]
US 7758891B2
· Desai et al.
· 2010
[cited by applicant]
US 7820788B2
· Desai et al.
· 2010
[cited by applicant]
US 7906121B2
· Chang et al.
· 2011
[cited by applicant]
US 7923536B2
· Desai et al.
· 2011
[cited by applicant]
US 8034375B2
· Desai et al.
· 2011
[cited by applicant]
US 8119129B2
· Jure-Kunkel et al.
· 2012
[cited by applicant]
US 8138229B2
· Desai et al.
· 2012
[cited by applicant]
US 8268348B2
· Desai et al.
· 2012
[cited by applicant]
US 8314156B2
· Desai et al.
· 2012
[cited by applicant]
US 8344177B2
· Neri et al.
· 2013
[cited by applicant]
US 8735394B2
· Desai et al.
· 2014
[cited by applicant]
US 8853260B2
· Desai et al.
· 2014
[cited by applicant]
US 9101543B2
· Desai et al.
· 2015
[cited by applicant]
US 9387244B2
· Markovic
· 2016
[cited by applicant]
US 9427477B2
· Markovic et al.
· 2016
[cited by applicant]
US 9446148B2
· Markovic et al.
· 2016
[cited by applicant]
US 9466148B2
· Gay et al.
· 2016
[cited by applicant]
US 9533058B2
· Markovic et al.
· 2017
[cited by applicant]
US 9555128B2
· Markovic et al.
· 2017
[cited by applicant]
US 9566350B2
· Markovic et al.
· 2017
[cited by applicant]
US 9757453B2
· Markovic et al.
· 2017
[cited by applicant]
US 20020111362A1
· Rubinfeld
· 2002
[cited by applicant]
US 20040077601A1
· Adams et al.
· 2004
[cited by applicant]
US 20070166388A1
· Desai et al.
· 2007
[cited by applicant]
US 20090004118A1
· Nie et al.
· 2009
[cited by applicant]
US 20100047234A1
· Markovic
· 2010
[cited by applicant]
US 20100112077A1
· Desai et al.
· 2010
[cited by examiner]
US 20110014117A1
· Wang et al.
· 2011
[cited by applicant]
US 20110076273A1
· Adler et al.
· 2011
[cited by applicant]
US 20110150902A1
· Markovic
· 2011
[cited by applicant]
US 20110262525A1
· Wang et al.
· 2011
[cited by applicant]
US 20120263739A1
· Langer et al.
· 2012
[cited by applicant]
US 20120315273A1
· Markovic
· 2012
[cited by applicant]
US 20130028895A1
· Wulf
· 2013
[cited by applicant]
US 20130071403A1
· Rolland et al.
· 2013
[cited by applicant]
US 20140155344A1
· Desai et al.
· 2014
[cited by applicant]
US 20140302017A1
· Markovic
· 2014
[cited by applicant]
US 20150050356A1
· Desai et al.
· 2015
[cited by applicant]
US 20160250351A1
· Markovic et al.
· 2016
[cited by applicant]
EP 1913947A1
· 2008
[cited by applicant]
EP 3204413
· 2017
[cited by applicant]
EP 3533870
· 2019
[cited by applicant]
JP S60146833
· 1985
[cited by applicant]
JP S6178731
· 1986
[cited by applicant]
JP H04504253
· 1992
[cited by applicant]
JP 2012522809
· 2012
[cited by applicant]
KR 1020090078330
· 2009
[cited by applicant]
RU 2011133819
· 2013
[cited by applicant]
WO WO8910398A1
· 1989
[cited by applicant]
WO WO9749390A1
· 1997
[cited by applicant]
WO WO9900113A1
· 1999
[cited by applicant]
WO WO9951248A1
· 1999
[cited by applicant]
WO WO2004096224A2
· 2004
[cited by applicant]
WO 2006034455
· 2006
[cited by applicant]
WO 2006089290
· 2006
[cited by applicant]
WO 2007027819
· 2007
[cited by applicant]
WO 2007027941
· 2007
[cited by applicant]
WO 2008047272
· 2008
[cited by applicant]
WO 2008057561
· 2008
[cited by applicant]
WO WO2008057562A1
· 2008
[cited by applicant]
WO WO2008112987A1
· 2008
[cited by applicant]
WO WO2009043159A1
· 2009
[cited by applicant]
WO WO2009055343A2
· 2009
[cited by applicant]
WO WO2010003057A2
· 2010
[cited by applicant]
WO WO2010017216A2
· 2010
[cited by applicant]
WO 2010118365
· 2010
[cited by applicant]
WO WO2010124009
· 2010
[cited by applicant]
WO 2010136492
· 2010
[cited by applicant]
WO WO2012048223A1
· 2012
[cited by applicant]
WO WO2012088388A2
· 2012
[cited by applicant]
WO WO2012154861A2
· 2012
[cited by applicant]
WO 2014037422
· 2014
[cited by applicant]
WO WO2004022097A1
· 2014
[cited by applicant]
WO WO2014055415A1
· 2014
[cited by applicant]
WO 2014105644
· 2014
[cited by applicant]
WO WO2015048520
· 2015
[cited by applicant]
WO WO2015191969A1
· 2015
[cited by applicant]
WO WO2015195476A1
· 2015
[cited by applicant]
WO WO2016057554A1
· 2016
[cited by applicant]
WO WO2016059220A1
· 2016
[cited by applicant]
WO WO2016089873
· 2016
[cited by applicant]
WO 2017031368
· 2017
[cited by applicant]
WO 2017062063
· 2017
[cited by applicant]
WO 2017120501
· 2017
[cited by applicant]
WO WO2017139698A1
· 2017
[cited by applicant]
WO 2017165439
· 2017
[cited by applicant]
WO 2017165440
· 2017
[cited by applicant]
WO 2017176265
· 2017
[cited by applicant]
WO 2018027205
· 2018
[cited by applicant]
WO 2018045238
· 2018
[cited by applicant]
WO 2018045239
· 2018
[cited by applicant]
WO 2018048815
· 2018
[cited by applicant]
WO 2018048816
· 2018
[cited by applicant]
WO 2018048958
· 2018
[cited by applicant]
Jazirehi et al. “Rituximab (anti-CD20) selectively modifies Bcl-xl and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis”…
[cited by examiner]
Lloyd et al. (Protein Engineering, Design & Selection 2009, 22:159-168).
[cited by examiner]
Beers et al. Seminars in Hematology, vol. 47, No. 2, Apr. 2010, pp. 107-114.
[cited by examiner]
Sehn et al. (Blood 2007, 109:4171-4173).
[cited by examiner]
Agarwal et al., “Flow Cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of Superficial Transitional cell carcinoma of bladder”, Cancer Immunol. Immunother., 20…
[cited by applicant]
Agarwala et al., “Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma”, J. Clin. Oncol., 2007, 25(18S):8510 (Abstract).
[cited by applicant]
Allen, TM, “Ligand-targeted therapeutics in anticancer therapy, Cancer”, Oct. 2002, 2(10), pp. 750-763.
[cited by applicant]
Alley et al., “Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates”, Bioconjugate Chem., 2008, 19(3), pp. 759-765.
[cited by applicant]
Arakawa et al., “Protein-Solvent Interactions in Pharmaceutical Formulations”, Pharm. Res., Mar. 1991, vol. 8, Issue 3, pp. 285-291.
[cited by applicant]
Asadullah et al., “Interleukin-10 therapy—review of a new approach”, Pharmarcol Rev., 2003, 55(2):241-269.
[cited by applicant]
Atkins et al., “High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update”, Cancer J Sci Am., 2000, Suppl 6:S11-14.
[cited by applicant]
Atkins, Michael, “Interleukin-2: clinical applications”, Semin Oncol., 2002, 29(3 Suppl 7):12-27.
[cited by applicant]
Bairagi et al., Albumin: A Versatile Drug Carrier, Austin Therapeutics, (Nov. 17, 2015) vol. 2, No. 2, p. 1021 (pp. 1-6), especially abstract, p. 2, Table 2, p. 2 col. 2 para. 2.
[cited by applicant]
Balch et al., “The new melanoma staging system”, Semin Cutan Med Surg., 2003, 22(1):42-54.
[cited by applicant]
Balch et al., “Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate”, Journal of Surgical Oncology, Aug. 19, 2011, vol. 104, Issue 4, pp. 379-385.
[cited by applicant]
Baumgartner et al., “Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells”, J Surg Res., 2007, 141(1): 72-77.
[cited by applicant]
Belani et al., “Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation”, J. Clin. Oncol., 2003, 21:…
[cited by applicant]
Bird et al., “Single-chain antigen-binding proteins”, Science, Oct. 1988, 242(4877), pp. 423-426.
[cited by applicant]
Boasberg et al., “Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma”, Journal of Clinical Oncology, May 20, 2011, vol. 29, No. 15 Supp, 8543.
[cited by applicant]
Boasberg et al., Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma, J Clin Oncol., 27:15s, 2009 (suppl; abstr 9061), 2009 ASCO Annual Meeting, Retrieved from th…
[cited by applicant]
Bolstad et al., “A comparison of normalization methods for high density oligonucleotide array data based on variance and bias”, Bioinformatics, 2003, 19:185-193.
[cited by applicant]
Cao et al., “Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab”, Clin Transl Oncol, 2007, 9:119-120.
[cited by applicant]
Carson et al., “A phase 2 trial of a recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma”, Proceedings of the ASCO vol. 22, No. 2873, General Post…
[cited by applicant]
Celis, “Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction”, Cancer, 2007, 110(1):203-214.
[cited by applicant]
Chapman et al., “Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation”, The New England Journal of Medicine, Jun. 30, 2011, vol. 364, Issue 26, pp. 2507-2516.
[cited by applicant]
Chisholm et al., “Response to influenza immunization during treatment for cancer”, Arch Dis Child, 2001, 84(6):496-500.
[cited by applicant]
Chong et al., “Combining cancer vaccines with chemotherapy”, Expert Opin Pharmacother., 2006, 6(16):2813-2820.
[cited by applicant]
Cleland et al., “The Development of Stable Protein Formulations: A close look at protein aggregation, deamidation, and oxidation”, Therapeutic Drug Carrier Systems, 1993, 10(4), pp. 307-377.
[cited by applicant]
Davis, “Affinity separation of antibody-toxin conjugate from albumin-stabilized formulation”, Am Biotechnol Lab., 12(4):60-64, Mar. 1994.
[cited by applicant]
Degrasse, J.A., “A Single-Stranded DNA Aptamer That Selectively Binds to
[cited by applicant]
Deguchi et al., “Effect of Methotrexate-Monoclonal Anti-Prostatic Acid Phosphatase Antibody Conjugate on Human Prostate Tumor”, Cancer Research, Aug. 1986, 46, pp. 3751-3755.
[cited by applicant]
Demirkesen et al., “The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic g…
[cited by applicant]
Denardo et al., “Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression”, Breast Cancer Res., 2007, 9(4):212.
[cited by applicant]
Desai et al., “Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel”, Clin Can…
[cited by applicant]
Deweers et al., “Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors”, J. Immunol., 186(3): 1840-1848, Feb. 1, 2011.
[cited by applicant]
Dudek et al., “Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma”, Am. J. Clin. Oncol., Apr. 1, 2008, 31(2):173-181.
[cited by applicant]
Elbayoumi et al., “Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody”, Clin Cancer Res., 2009, 15(6):19…
[cited by applicant]
Ellyard et al., “Th2-mediated anti-tumour immunity: friend or foe?”, Tissue Antigens, 2007, 70(1):1-11.
[cited by applicant]
Elsadek et al., “Impact of albumin on drug delivery—New applications on the horizon”, J of Controlled Release, 2011, 1-25.
[cited by applicant]
Ferrara et al., “The biology of VEGF and its receptors”, Nat. Med., 2003, 9:669-676.
[cited by applicant]
Flaherty et al., “Final Results of E2603: a double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel(P) with or without sorafenib(S) in metastatic melanoma”, J. Clin Oncol., 2010, 28:15s (suppl: abs…
[cited by applicant]
Folkman, J., “Angiogenesis in cancer, vascular, rheumatoid and other disease”, Nat. Med., 1995, 1, 27-31.
[cited by applicant]
Fricke et al., “Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses”, Clin. Cancer Res., 2007, 13:4840-4848.
[cited by applicant]
Gabrilovich et al., “Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells”, Nat. Med., 1996, 2: 1096-1103.
[cited by applicant]
Gao et al., “In vivo cancer targeting and imaging with semiconductor quantum dots”, Nat Biotech, 2004, 22(8):969-976.
[cited by applicant]
Gogas et al., “Chemotherapy for metastatic melanoma: time for a change?”, Cancer, 2007, 109(3): 455-464.
[cited by applicant]
Graells et al., “Overproduction of VEGF16s concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling”, J. Invest. Dermatol., 2004, 123:1151-1161.
[cited by applicant]
Gupta, I., et al., “Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies,” Ann. N.Y. Acad. Sci., 1263, pp. 43-56 (Jul. 25, 2012).
[cited by applicant]
Haley et al., “Nanoparticles for drug delivery in cancer treatment”, Urol. Oncol.: Seminars and Original Invest., 2008, 26:57-64.
[cited by applicant]
Hauschild et al., “Individualized therapy of disseminated cancer using malignant melanoma as a model”, Cancer and Metastasis Reviews, 2006, 25(2): 253-256.
[cited by applicant]
Hauschild et al., “Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination with Carboplatin and Paclitaxel as Second-Line Treatment in Patients with Unresectable Stage III or Stage IV Me…
[cited by applicant]
Hersh et al., “A Phase 2 Clinical Trial of nab-Paclitaxel in Previously Treated and Chemotherapy-Naïve Patients With Metastatic Melanoma”, Cancer, Jan. 1, 2010, 116:155, pp. 155-163.
[cited by applicant]
Hersh et al., “A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma”, Ann Oncol, 2015, epub Sep. 26, 2015.
[cited by applicant]
Hersh et al., “Open-label, multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma”, J. Clin. Oncol., 2005, 23(16S):7558 (Abstract).
[cited by applicant]
Hobbs et al., “Regulation of Transport pathways in tumor vessels: role of tumor type and microenvironment”, Proc Natl Acad Sci USA, Apr. 1998, 95, pp. 4607-4612.
[cited by applicant]
Hodi et al., “Improved survival with ipilimumab in patients with metastatic melanoma”, The New England Journal of Medicine, Aug. 19, 2010, vol. 363, No. 8, pp. 711-723.
[cited by applicant]
Hodi et al., “Phase II study of paclitaxel and carboplatin for malignant melanoma”, Am. J. Clin. Oncol., 2002, 25:283-286.
[cited by applicant]
Huncharek et al., “Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials”, Melanoma Research, 11:75-81 (2001).
[cited by applicant]
Hunkapiller et al., “Immunology: The growing immunoglobulin gene superfamily”, Nature, Sep. 1986, 323, pp. 15-16.
[cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Ibrahim et al., “Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel”, Clinical Cancer Research, May 2002, vol. 8, pp. 1038-1044.
[cited by applicant]
Inagaki et al., “Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: High interleukin-5 and -10 levels are significant unfavorable prognostic factors”…
[cited by applicant]
Jain et al., “Delivering nanomedicine to solid tumors”, Nature Reviews Clinical Oncology, Nov. 2010, 7, pp. 653-664.
[cited by applicant]
Jiang et al., “Regulation of Immune Responses by T Cells”, N Engl J Med., 2006, 354(11): 1166-1176.
[cited by applicant]
Julien et al, “Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer”, 2011, MAbs, 3:467-478.
[cited by applicant]
Kamat et al., “Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer”, Cancer Res., 2007, 67(1):281-288.
[cited by applicant]
Kawai et al., “VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients”, Lung Cancer, 2008, 59(1):41-47.
[cited by applicant]
Kikuchi et al., “Vascular endothelial growth factor and dendritic cells in human squamous cell carcinoma of the oral cavity”, Anticancer Res., 2006, 26(3A):1833-1848.
[cited by applicant]
Kim et al., “A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor a ameliorates experimental arthritis”, Scientific Reports, 2016, pp. 1-12.
[cited by applicant]
Kim et al., “BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination with Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma”, Journal of Clinical Oncolog…
[cited by applicant]
Kirkwood et al., “A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma”, Clin Cancer Res., 2004, 10(5):1670-1677.
[cited by applicant]
Kondejewski et al., “Synthesis and characterization of carbohydrate-linked murine monoclonal antibody K20-human serum albumin conjugates”, Bioconjug Chem., 5(6):602-611, Nov.-Dec. 1994.
[cited by applicant]
Korman et al., “Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies”, Curt Opin Invest Drugs, 2005, 6(6):582-591.
[cited by applicant]
Kottschade et al., “A Phase II Trial of Nab-Paclitaxel (ABI-007) and Carboplatin in Patients with Unresectable Stage IV Melanoma”, Cancer, Apr. 15, 2011, 117(8), pp. 1704-1710.
[cited by applicant]
Kottschade et al., “A Randomized Phase 2 Study of Temozolomide and Bevacizumab or nab-Paclitaxel, Carboplatin, and Bevacizumab in Patients with Unresectable Stage IV Melanoma”, Cancer, 2013, vol. 119, Issue 3, pp. 586-5…
[cited by applicant]
Kratz et al., “Serum proteins as drug carriers of anticancer agents: a review”, Drug Deliv., 5(4):281-299, 1998.
[cited by applicant]
Kratz, “Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles”, J Control Release, 132(3):171-183, Epub May 17, 2008.
[cited by applicant]
Krishnan et al., “Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease”, Transpl Infect Dis., 12(4):363-70, print Aug. 2010, ePub Jan. 2010.
[cited by applicant]
Kukowska-Latallo et al., Nanoparticle Targeting of Anticancer Drug Improves Therapeutic Response in Animal Model of Human Epithelial Cancer, Cancer Res, 2005, 65(12):5317-5324.
[cited by applicant]
Kumar et al., Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients, Oncol. Rep., 2006, 15(6):1513-1516.
[cited by applicant]
Lanzavecchia et al., “The use of hybrid hybridomas to target human cytotoxic T lymphocytes”, Eur. J. Immunol., 1987, 17, pp. 105-111.
[cited by applicant]
Lau et al., Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?, Anti-Cancer Drugs, 2004, 15:871-875.
[cited by applicant]
Lei et al., Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms, Nanomed: Nanotech, Biol, and Med., 2011, 7:324-332.
[cited by applicant]
Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy, Mol. Cancer Ther., 2003, 2:753-763.
[cited by applicant]
Lev et al., Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo, J. Clin. Oncol., 2004, 22:2092-2100.
[cited by applicant]
Lin, S.Y, “Salmon calcitonin: conformational changes and stabilizer effects”, AIMS Biophysics, 2015, 2(4): 695-723.
[cited by applicant]
Lundin et al., Phase 2 Study of Alemtuzumab (anti-CD52 Monoclonal Antibody)in Patients with Advanced Mycosis Fungoides/Sezary Syndrome, Blood. (Jun. 1, 2003) vol. 101, No. 11, pp. 4267-4272, especially p. 4267 col. 1, p…
[cited by applicant]
Marcoval et al., Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase, J. Cutan. Pathol., 1997, 24:212-218.
[cited by applicant]
Markovic et al., A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma, Am. J. Clin. Oncol., 2007, 30(3):303-309.
[cited by applicant]
Markovic et al., A reproducible method for the enumeration of functional ( cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood, Clin. Exo. Immunol., 2006, 145:438…
[cited by applicant]
Markovic et al., Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization, Am J Clin Oncol., 2006, 29(4):352-360.
[cited by applicant]
Matejtschuk, P., “Lyophilization of Proteins”, Methods in Molecular Biology, Cryopreservation and Freeze-Drying Protocols, Second Edition, Edited by: J. G. Day and G. N. Stacey © Humana Press Inc., Totowa, NJ, 2007, vol…
[cited by applicant]
Matsuda et al., Preoperative oral immune-enhancing nutritional supplementation corrects TH1/TH2 imbalance in patients undergoing elective surgery for colorectal cancer, Dis. Colon Rectum, 2006, 49(4):507-516.
[cited by applicant]
Mayo Clinic: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery—Full Text View ClinicalTrials.gov, Dec. 19, 2013, pp. 1-4…
[cited by applicant]
McElroy et al., Imaging of Primary and Metastatic Pancreatic Cancer Using a Fluorophore-Conjugated Anti-CA19-9 Antibody for Surgical Navigation, World J Surg., 2008, 32: 1057-1066.
[cited by applicant]
Melcher, Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy, Clin Oncol (R Coll Radiol), 2005, 17(1): 12-15.
[cited by applicant]
Merchan et al., Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition, Int. J. Cancer, 2005, 113, pp. 490-498.
[cited by applicant]
Mezzaroba et al., “New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles”, Sep. 2103, PLoS One vol. No. 8, Issue 9 pp. 1-10, e74…
[cited by applicant]
Middleton et al., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma, J. Clin. Oncol., 2000, 18, pp. 158-166.
[cited by applicant]
Miller et al. “Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer,” N Engl. J Med., (2007) vol. 357:2666-2676.
[cited by applicant]
Mimura et al., Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2, Cancer Immunol Immunother., 2007, 56(6). pp. 761-770.
[cited by applicant]
Mirtsching et al., “A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer”, Clinical Breast Cancer, 2011, 11(2):121-128.
[cited by applicant]
Mocellin et al., Cytokines and immune response in the tumor microenvironment, J Immunother., 2001, 24(5), pp. 392-407.
[cited by applicant]
Motl, S., Bevacizumab in combination chemotherapy for colorectal and other cancers, Am. J. Health-Syst. Pharm 2005, 62:1021-1032.
[cited by applicant]
Ng et al., Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel, Clin. Cancer Res., 2006, 12, pp. 4331-4338.
[cited by applicant]
Ng et al., Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins, Cancer Res., 2004, 64, pp. 821-824.
[cited by applicant]
Nilvebrant et al., “The Albumin-Binding Domain as a Scaffold for Protein Engineering”, Computational and Structural Biotechnology Journal, Mar. 2013, vol. 6, Issue 7, e201303099, http://dx.doi.org/10.5936/csbj.201303099.
[cited by applicant]
Oku et al., Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and pro…
[cited by applicant]
Parikh et al., The vascular endothelial growth factor family and its receptors, Hematol. Oncol. Clin. N. Am., 2004, 18, pp. 951-971.
[cited by applicant]
Park et al., Anti-HER2 Immunoliposomes: Enhanced Efficacy Attributable to Targeted Delivery, Clin. Cancer Res., 2002, 8, pp. 1172-1181.
[cited by applicant]
Perez et al., “Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma,” A north central cancer treatment group study, Cancer, 2009, 115(1), pp. 119-127.
[cited by applicant]
Phase II: A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma (BEAM) Mar. 12, 2007, [retrieved Mar. 15, 2010]. Retrieved from the Interne…
[cited by applicant]
Pikal, M., Freeze-drying of proteins, Part II: Formulation selection, Biopharm, 1990, 9, pp. 26-30.
[cited by applicant]
Polak et al., Mechanisms of local immunosuppression in cutaneous melanoma, Br J Cancer, 2007, 96(12), pp. 1879-1887.
[cited by applicant]
Porrata et al., Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma, Blood, 2001, 98(3), pp. 579-585.
[cited by applicant]
Porrata et al., Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation, Clin Exp Med., 2004, 4(2):78-85.
[cited by applicant]
Powell et al., Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion, J Immunol., 2006, 177(9), pp. 6527-6539.
[cited by applicant]
Pries et al., Cytokines in head and neck cancer, Cytokine Growth Factor Rev., 2006, 17(3), pp. 141-146.
[cited by applicant]
Ranieri et al., “Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic”, Curr. Med. Chem., 2006, 13, 1845-1857.
[cited by applicant]
Rao et al., “Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma”, Cancer, 2006, 106(2), 375-382.
[cited by applicant]
Ribas et al., “Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206”, J Clin Oncol., Dec. 10, 2005, 23(35), p…
[cited by applicant]
Rosenberg et al., “Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma”, J. Immunol., 2005, 175(9), pp. 6169-6176.
[cited by applicant]
Roy et al., “Tumor associated release of interleukin-10 alters the prolactin receptor and down—regulates prolactin responsiveness of immature cortical thymocytes”, J Neuroimmunol., 2007, 186(1-2), pp. 112-120.
[cited by applicant]
Rudnicka et al., “Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity”, Blood, 2013, 121(23):4694-4702.
[cited by applicant]
Sadat et al., “Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer”, Current Cancer Drug Targets, 2015, 15(1):71-86.
[cited by applicant]
Salven et al., “Enhanced expression of vascular endothelial growth factor in metastatic melanoma”, Br. J. Cancer, 1997, 76(7), pp. 930-934.
[cited by applicant]
Sandler et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer”, N. Engl. J. Med., 2006, 355:2542-2550.
[cited by applicant]
Sato et al., “Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer”, Proc Natl Acad Sci USA, 2005, 102(51):18538-18543.
[cited by applicant]
Schrama et al., “Antibody targeted drugs as cancer therapeutics, Nature Reviews Drug Discovery”, Feb. 2006, 5, pp. 147-159.
[cited by applicant]
Sester et al., “Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation”, Am J Transplant., 5(6):1483-1489, Jun. 2005.
[cited by applicant]
Srivastava et al., “Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications”, Microsc. Res. Tech., 2003, 60:208-224.
[cited by applicant]
Streit et al., “Angiogenesis, lymphangiogenesis, and melanoma metastasis”, Oncogene, 2003, 22, pp. 3172-3179.
[cited by applicant]
Taieb et al., “Chemoimmunotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines”, J. Immunol., Mar. 1, 2006, 176(5):2722-2729.
[cited by applicant]
Tao et al., “Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach”, Br. J. Dermatol., 2005, 153:715-724.
[cited by applicant]
Tas et al., “Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients”, Melanoma Res., 2006, 16:405-411.
[cited by applicant]
Terheyden et al., “Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasizing melanoma”, J Cancer Res Clin Oncol, 2007, 133(11), pp. 897-901.
[cited by applicant]
Ugurel et al., “Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival”, J. Clin. Oncol., 2001, 19:577-583.
[cited by applicant]
Vacca et al., “Docetaxel versus paclitaxel for antiangiogenesis”, J. Hematother. Stem Cell Res., 2002, 11:103-118.
[cited by applicant]
Varker et al., “A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma”, Ann Surg Oncol., 14(8):2367-2376, print Aug. 2007, Epub May 2007.
[cited by applicant]
Vence et al., “Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma”, Proc Natl Acad Sci USA, 2007, 104(52), pp. 20884-20889.
[cited by applicant]
Wagner et al., “Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles”, Biomaterials., 31(8):2388-2398, Epub Dec. 23, 2009.
[cited by applicant]
Walker et al., “Monitoring immune responses in cancer patients receiving tumor vaccines”, Int Rev Immunol., 2003, 22(3-4):283-319.
[cited by applicant]
Wang et al., “Biofunctionalized targeted nanoparticles for therapeutic applications”, Expert Opin. Biol. Ther., 2008, 8(8): 1063-1070.
[cited by applicant]
Wang et al., “Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly”, Anti-Cancer Drugs, 2003, vol. 14, Issue 1, pp. 13-19.
[cited by applicant]
Weber, “Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events”, Oncologist, Jul. 2007, 12(7), pp. 864-872.
[cited by applicant]
Wiernik et al., “Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma”, Journal of Clinical Oncology, Aug. 1987, vol. 5, No. 8, pp. 1232-1239.
[cited by applicant]
Wong et al., “Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs”, Int. Immunol., 2007, vol. 19, No. 10, pp. 1223-1234.
[cited by applicant]
Wu et al., “Aptamers: Active Targeting Ligands for Cancer Diagnosis and Therapy”, Theranostics, 2015, 5(4):322-344.
[cited by applicant]
Yardley et al., “A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer”, Breast Cancer Res …
[cited by applicant]
Yee et al., “Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells”, Proc N…
[cited by applicant]
Yuan et al., “Vascular Permeability in a Human Tumor Xenograft: Molecular Size Dependence and Cutoff Size”, Cancer Research, Sep. 1, 1995, 55, pp. 3752-3756.
[cited by applicant]
Zimpfer-Rechner et al., “Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Gr…
[cited by applicant]
Vishnu, P. et al., Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer, Breast Cancer: Basic and Clinical Research, vol. 5, pp. 53-65 (2011).
[cited by applicant]
Adams S, et al, “(P2-11-01) Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatictriple-negative breast cancer”, 2015, 1 page.
[cited by applicant]
Alessandra Fabi et al, “Prospective study on nanoparticle albumin-bound paclitaael in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients”, Drug Design, Development and The…
[cited by applicant]
Anonymous: “A Phase III, Multicenter, Randomized Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Nab Paclitaxel Compared with Placebo with Nab Paclitaxel for Patients with Previously U…
[cited by applicant]
Anonymous: “Atezolizumba Plus Abraxane Promising New Treatment for Triple-Negative Breast Cancer”, UNM Comprehensive Cancer Center, Jan. 7, 2016, pp. 1-2.
[cited by applicant]
Armitage, J.O. & Weisenburger, D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16, 2780-2795 (199…
[cited by applicant]
Edison, “MorphoSys,” 16 pages (Aug. 8, 2013).
[cited by applicant]
Emens L et al, (OT1-01-06) A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC), 2015, 2 pages.
[cited by applicant]
Erika Hamilton et al, “Nab-Paclitaxel/Bevacizumba/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer”, Clinical Breast Cancer, vol. 13, No. 6, Dec. 1, 2013, 6 pages.
[cited by applicant]
Giorgio Mustacchi et al, “The role of taxanes in triple-negative breast cancer: literature review”, Drug Design, Development and Therapy, vol. 9, Aug. 5, 2015, 16 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2017/050137, Nov. 27, 2017, 17 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2017/045643, Oct. 25, 2017, 16 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2017/049745, Mayo Foundation for Medical Education and Research, 13 pages (Dec. 15, 2017).
[cited by applicant]
International Search Report and Written Opinion, PCT/US2017/049746, Nov. 27, 2017, 15 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2017/050134, Nov. 16, 2017, 17 pages.
[cited by applicant]
Kazuhiro Nishida et al, English Translation of “Clinical Trails of New Drugs Cytotoxic Effect against Multiple Myeloma with High Expression of a CD38 Antigen and a Human CD38 Monoclonal Antibody Daratumumab:CD38 Antigen…
[cited by applicant]
Lisa D Volk-Draper et al, “Novel Model for Basaloid Triple-negative Breast Cancer: Behavior In Vivo and Response to Therapy”, vol. 14, No. 10, Oct. 1, 2012, 18 pages.
[cited by applicant]
Nahleh et al, “Swog S0800 (NCI CDR0000636131): addition of bevacizumba to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or …
[cited by applicant]
Silas Inman, “Atezolizumab/Nab-Paclitaxel Combo Shows High Response Rates in TNBC”, OneLive, Dec. 10, 2015, 4 pages.
[cited by applicant]
Sylvia Adams et al., “Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC)” Journal of Clinical Oncology col. 34, No. 15, May 1, 2016, 4 pag…
[cited by applicant]
Wendy K. Nevala et al, “Abstract B77: Targets nano-immune conjugates to melanoma: Preclinical testing of bevacizumab targeted nab-paclitaxel”, Cancer Immunology Research, vol. 3, Oct. 1, 2015, 3 pages.
[cited by applicant]
Wendy K. Nevala et al., “Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20 B-cell lymphoma”, Scientific Reports, vol. 7, Apr. 5, 2017, 9 pages.
[cited by applicant]
Wendy K. Nevala et al, “Antibody-Targeted Chemotherapy for the Treatment of Melanoma”, Cancer Research, vol. 76, No. 13, Jul. 1, 2016, pp. 3954-3964.
[cited by applicant]
Wendy K. Nevala et al, “Targeted nano-immune conjugates to melanoma: Preclinical testing of bevacizumab targeted nab-paclitaxel”, Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Cha…
[cited by applicant]
Yashito Terui, English Translation of Molecular-Targeted Therapy for Cancer: Progresses and Challenges, “Daratumumab, Antibody Drug against Myeloma”, Pharma Med., Nov. 10, 2013, vol. 31, No. 11, p. 27-30.
[cited by applicant]
Lee, A, et al., “The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles”, Biomaterials Elsevier Science Publishers BV., Barking, GB, vol. 30, No. 5, Feb. 1, 2009, pp. 919-927.
[cited by applicant]
Parker, Edward et al., “Targeting CLL Cells Using Ritumixab-Conjugated Surface Enhanced Raman Scattering (SERS) Gold Nanoparticles”, Blood, American Society of Hematology, US, vol. 116, No. 21, Nov. 1, 2010, p. 1109.
[cited by applicant]
Washington University School of Medicine “Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma”, ClinicalTrials.gov, Dec. 6, 2016, 7 pages.
[cited by applicant]
U.S. Appl. No. 14/116,619, office action mailed Feb. 4, 2015.
[cited by applicant]
U.S. Appl. No. 14/116,619, office action mailed Apr. 28, 2016.
[cited by applicant]
U.S. Appl. No. 14/116,619, office action mailed Sep. 10, 2015.
[cited by applicant]
U.S. Appl. No. 14/432,979, office action mailed May 16, 2018.
[cited by applicant]
U.S. Appl. No. 14/432,979, office action mailed Jun. 30, 2016.
[cited by applicant]
U.S. Appl. No. 14/432,979, office action mailed Oct. 4, 2017.
[cited by applicant]
U.S. Appl. No. 14/432,979, office action mailed Dec. 15, 2016.
[cited by applicant]
U.S. Appl. No. 14/882,327, office action mailed May 2, 2016.
[cited by applicant]
U.S. Appl. No. 15/030,567, office action mailed Sep. 7, 2016.
[cited by applicant]
U.S. Appl. No. 15/030,568, office action mailed May 25, 2017.
[cited by applicant]
U.S. Appl. No. 15/030,568, office action mailed Jun. 18, 2018.
[cited by applicant]
U.S. Appl. No. 15/030,568, office action mailed Dec. 1, 2017.
[cited by applicant]
U.S. Appl. No. 15/052,336, office action mailed Feb. 9, 2018.
[cited by applicant]
U.S. Appl. No. 15/052,623, office action mailed Feb. 9, 2018.
[cited by applicant]
U.S. Appl. No. 15/052,623, office action mailed May 19, 2017.
[cited by applicant]
U.S. Appl. No. 15/052,623, office action mailed Jul. 9, 2018.
[cited by applicant]
U.S. Appl. No. 15/052,623, office action mailed Nov. 25, 2016.
[cited by applicant]
U.S. Appl. No. 15/060,967, office action mailed Aug. 2, 2016.
[cited by applicant]
U.S. Appl. No. 15/064,396, office action mailed Aug. 9, 2016.
[cited by applicant]
U.S. Appl. No. 15/092,403, office action mailed Apr. 2, 2018.
[cited by applicant]